Biocide active substance redefinitions under the SPS Agreement

A redefinition occurs when the identity of an active substance that is already included in the Review Programme is clarified or changed during the assessment of the substance for one or more product types. When this happens, the substance that was previously covered by a single active substance definition is redefined and given a new or more specific name. The previously defined active substance is then subject to an open invitation for someone to take over support.

If a person notifies their interest in supporting that active substance and subsequently submits the required dossier, the original substance goes back to the Review Programme for assessment. If no notification is submitted, or the required dossier is not subsequently submitted, a non-approval decision will ultimately be taken for that active substance/product type combination.

Meanwhile, the assessment of the newly redefined active substance continues separately, and a separate decision on its approval is taken.

Sometimes, an active substance may be renamed during the assessment process if it is agreed that a different name more accurately describes the chemical substance. In these cases, only the name changes and the identity of the active substance remains the same. Therefore, there is no need to seek a new supporter for the previous name, and the main regulatory consequence is the need to update the labelling of affected biocidal products.

Relevant to this guidance, a number of active substances have been renamed, but only 2 have been redefined:

  • ‘poly(oxy-1,2-ethanediyl), α-[2-(didecylmethylammonio)ethyl]- ω-hydroxy-, propanoate (salt) (Bardap 26)’
  • ‘garlic, ext. Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, etc., obtained from Allium sativum, Liliaceae’

If your product contains either of these 2 active substances, you will need to take action to ensure that either you change to the newly redefined active substance or stop making your products available on the GB market by 31 May 2028. Use of products containing these active substances should cease by 30 November 2028.

Poly(oxy-1,2-ethanediyl), α-[2-(didecylmethylammonio)ethyl]- ω-hydroxy-, propanoate (salt) (Bardap 26)

This active substance was redefined in the EU as ‘reaction mass of N,N-didecyl-N-(2-hydroxyethyl)-N-methylammonium propionate and N,N-didecyl-N-(2-(2-hydroxyethoxy)ethyl)-N-methylammonium propionate and N,N-didecyl-N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methylammonium propionate’. It is currently approved in the EU for product types 2, 4 and 8, and under review for product type 10.

The actions you will be required to take after 1 March 2028 will depend on the combination of the EU status and the GB status, however, in all cases you will need to ensure that you change your active substance to ‘reaction mass of N,N-didecyl-N-(2-hydroxyethyl)-N-methylammonium propionate and N,N-didecyl-N-(2-(2-hydroxyethoxy)ethyl)-N-methylammonium propionate and N,N-didecyl-N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-N-methylammonium propionate’ if your product contains ‘Bardap 26’. Your product’s formulation and labelling will have to reflect this change.

Where BPR product authorisations exist, before 1 March 2028, these will need to be changed to reflect the change in the active substance. Likewise, where Control of Pesticides Regulations (COPR) approvals exist, they will need to be amended.

a. Product type 2

The redefined active substance was approved in the EU for product type 2 (disinfectants and algaecides not intended for direct application to humans or animals) in September 2023, while Bardap-26 is still under review in GB. A non-approval decision was made for Bardap-26 (i.e. the previous active substance identity) in product type 2 in the EU in March 2024.

The newly redefined active substance is in scenario 5a for product type 2. This means that after 1 March 2028, BPR authorisation is required to maintain market access. Applications for authorisation must be made to HSE by 31 August 2028. Further details about how to apply under the EU system will be provided when available. During the application and evaluation process products will remain subject to existing GB national rules, for example COPR.

Articles treated with biocidal products containing these active substance/product type combinations can continue to be placed on the market. However, all treated articles placed on the market after 31 August 2028 must comply with any restrictions or specific labelling conditions imposed by the approval renewal decision.

If you want to bring a new product within scope of COPR to the market, you should apply for COPR approval by at least 6 months before the deadline to submit your BPR product authorisation application otherwise you will have to wait until the BPR authorisation is granted before you could bring the product to the market.

b. Product type 4

The redefined active substance was approved in the EU for product type 4 (disinfectants on food and feed areas) in September 2023, whereas Bardap-26 received a non-approval decision in February 2024 in GB. A non-approval decision was also made for Bardap-26 (i.e. the previous active substance identity) in product type 4 in the EU in March 2024.

The newly redefined active substance is in scenario 5g for product type 4 . If you want to supply biocidal products containing this active substance/product type combinations you must apply for BPR product authorisation by 31 August 2028. Further details about how to apply via the EU system will be provided when available. Note that you only need to apply for BPR product authorisation once the last active substance/product type combination in your product has been approved.

Guidance on the applicability of Article 89 transitional provisions while awaiting BPR product authorisation will be communicated when available.

c. Product type 8

The active substance was approved in the EU for product type 8 before the UK left the EU, and it is currently ‘approved under renewal’ in both jurisdictions. However, after EU Exit the EU redefined the active substance and amended the previous approval in September 2023.

The newly redefined active substance is in scenario 12 for product type 8. The approval expiry dates may differ between GB and the EU where expiry dates have been postponed during the on-going renewal process. Before 1 March 2028, the relevant GB and EU expiry dates continue to apply in their respective jurisdictions. After 1 March 2028, the EU expiry date will apply in GB.

An active substance that is ‘approved under renewal’ may be the subject of a renewal or non-renewal decision. If your product contains the newly redefined active substance in product type 8, monitor its EU status regularly in the SPS list of biocide active substances and ensure that you are subscribed to HSE’s ebulletins.

Articles treated with biocidal products containing this active substance/product type combination may continue to be placed on the GB market.

d. Product type 10

The active substance was redefined in the EU in accordance with the assessment carried out for product types 2 and 4. As happened with product types 2 and 4, a non-approval decision was also made for Bardap-26 (i.e. the previous active substance identity) in product type 10 in the EU in March 2024.

The newly redefined active substance is under review for product type 10 in both GB and the EU, so it is in scenario 13 for this product type. This means that biocidal products in this product type may be made available on the market subject to the requirements of national rules, including COPR product approvals when relevant.

If a decision on approval is taken in the EU, it will apply in GB from 1 March 2028. This will result in your active substance changing scenario. You should therefore monitor the EU status regularly. You can do this by checking the SPS biocide list of active substances or ECHA’s website.

Garlic, ext. Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, etc., obtained from Allium sativum, Liliaceae

This active substance was redefined in the EU as ‘thermally treated garlic juice’ and approved in product type 19 in March 2024, when the previous active substance ‘garlic, ext. Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, etc., obtained from Allium sativum, Liliaceae’ received a non-approval decision. The previous active substance identity is ‘under review’ in GB.

If you have a biocidal product that contains the previous active substance, you will need to change your active substance to the newly redefined ‘thermally treated garlic juice’. Your product’s formulation and labelling will have to reflect this change. Where COPR approvals exist, they will need to be amended to reflect the change in the active substance.

The newly redefined active substance is in scenario 5a for product type 19. This means that from 1 March 2028, BPR authorisation is required to maintain market access. Applications for authorisation must be made to HSE by 31 August 2028. Further details about how to apply under the EU system will be provided when available. During the application and evaluation process products will remain subject to their existing GB food and feed derogation. New products must wait for the BPR authorisation to be granted before placing the product on the market.

Articles treated with biocidal products containing this active substance/product type combination can continue to be placed on the market.

Disclaimer

This guidance is intended to help businesses prepare for implementation of the SPS Agreement. Details remain subject to legislative processes.

Is this page useful?

Updated 2026-11-20